The Short Bowel Syndrome drugs in development market research report provides comprehensive information on the therapeutics under development for Short Bowel Syndrome, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Short Bowel Syndrome. Buy the report here.

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Short Bowel Syndrome and features dormant and discontinued products.

GlobalData tracks 20 drugs in development for Short Bowel Syndrome by 19 companies/universities/institutes. The top development phase for Short Bowel Syndrome is preclinical with ten drugs in that stage. The Short Bowel Syndrome pipeline has 20 drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Short Bowel Syndrome pipeline products market are: Huons Global, 9 Meters Biopharma and QuiaPEG Pharmaceuticals.

The key targets in the Short Bowel Syndrome pipeline products market include Glucagon Like Peptide 2 Receptor (GLP2R), Glucagon Like Peptide 1 Receptor (GLP1R), and Cystic Fibrosis Transmembrane Conductance Regulator (ATP Binding Cassette Sub Family C Member 7 or Channel Conductance Controlling ATPase Camp Dependent Chloride Channel or ABCC7 or CFTR or EC

The key mechanisms of action in the Short Bowel Syndrome pipeline product include Glucagon Like Peptide 2 Receptor (GLP2R) Agonist with 11 drugs in Phase III. The Short Bowel Syndrome pipeline products include three routes of administration with the top ROA being Subcutaneous and nine key molecule types in the Short Bowel Syndrome pipeline products market including Small Molecule, and Recombinant Peptide.

Short Bowel Syndrome overview

Short bowel syndrome is a complex disease that occurs due to the physical loss or the loss of function of a portion of the small and/or large intestine. Symptoms include bloating, cramping, fatigue, heartburn, vomiting, weakness, and diarrhea. Complications of short bowel syndrome include malnutrition, peptic ulcers, kidney stones, and small intestinal bacterial overgrowth. Treatment includes vitamin and mineral supplements, antibiotics, proton pump inhibitors, and bile-salt binders.

For a complete picture of Short Bowel Syndrome’s pipeline drug market, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.